Baker Botts L.L.P., a leading international law firm, is representing its client Boehringer Ingelheim GmbH, one of the world’s leading pharmaceutical companies focusing on researching, developing, and marketing human health and animal health products, in certain proposed transactions with Sanofi.
Specifically, the Baker Botts team will lead the U.S. antitrust review of Boehringer Ingelheim’s purchase of Merial, Sanofi’s animal health unit, and its sale to Sanofi of Boehringer Ingelheim’s consumer health care division.
For more information, please see Boehringer Ingelheim’s news release by clicking here.
ABOUT BAKER BOTTS L.L.P.
Baker Botts is an international law firm of approximately 700 lawyers practicing throughout a network of 13 offices around the globe. Based on our experience and knowledge of our clients' industries, we are recognized as a leading firm in the technology, energy, and life sciences sectors. Since 1840, we have provided creative and effective legal solutions for our clients while demonstrating an unrelenting commitment to excellence. For more information, please visit bakerbotts.com.